Výsledky vyhledávání

Possible compensation in epidermal growth factor production by saliva in rat

Autor: Tivadar Zelles, K. Birki, István Kisfalvi, M. Wenczl, K. Offenmuller, József Blazsek, Beáta Burghardt, Gábor Varga

Publikováno v: Inflammopharmacology. 4:279-295

In the present work, the authors investigated the effect of both main vegetative transmitters and some regulatory peptides on epidermal growth factor (EGF) secretion into whole saliva. We studied how the salivary and glandular EGF levels depend on th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ba1c4007f7343bcd898e0a05deeec2a4
https://doi.org/10.1007/bf02731878

Zobrazit plný text záznamu

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction

Autor: L. Cisar, K. Wang, S Songül Yalçin, M. Dank, Erdem Göker, Christian Peschel, R. Bugat, J. Zaluski, V. Valvere, M. Wenczl, Carlo Barone

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 19(8)

PubMed ID: 18558665
Background: We aimed to establish the superiority (or noninferiority if superiority was not achieved) in terms of time to progression (TTP) of irinotecan/5-fluorouracil (IF) over cisplatin/5-fluorouracil (CF) in chemonaive pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22690b327254c9671c0912d9d7f0cd06
https://pubmed.ncbi.nlm.nih.gov/18558665

Zobrazit plný text záznamu

Delay in time to worsening of symptoms (TWS) of advanced non-small cell lung cancer (NSCLC) using gemcitabine (gem) maintenance therapy

Autor: Maciej Krzakowski, Tudor-Eliade Ciuleanu, Patrick Peterson, Astra M. Liepa, Thomas Brodowicz, Valentina Tzekova, Rodryg Ramlau, M. Wenczl, Christoph C. Zielinski, Matjaz Zwitter

Publikováno v: Journal of Clinical Oncology. 24:7140-7140

7140 Background: Palliation of disease-related symptoms is an important clinical benefit. For advanced disease, this may be relief or delay of worsening of symptoms. Since benefit evaluation in clinical trials is usually focused on radiological asses

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::122b70157dd3366c40451a3443bdbd50
https://doi.org/10.1200/jco.2006.24.18_suppl.7140

Zobrazit plný text záznamu

Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st-line advanced gastric cancer patients

Autor: J. Zaluski, Carlo Barone, L. Awad, Christian Peschel, M.-L. Risse, Erdem Göker, M. Dank, R. Bugat, V. Valvere, M. Wenczl

Publikováno v: Journal of Clinical Oncology. 23:4003-4003

4003 Background: An open-label, multicenter study of 1st-line advanced gastric cancer patients (pts) was designed to compare the effects of CPT-11 + 5FU/FA with CDDP + 5FU. Primary efficacy variable: time to progression (TTP); secondary endpoints: ti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1be2e0c02e12d6dcd615f6dc0b2882e9
https://doi.org/10.1200/jco.2005.23.16_suppl.4003

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání